Mingjia Li

Oncology

300 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifies EDNRB as a predictor of immunotherapy response.

Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifies EDNRB as a predictor of immunotherapy response.

Journal: Journal for immunotherapy of cancer

Published: June 29, 2026

Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.

Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.

Journal: The oncologist

Published: May 03, 2026

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.

Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.

Journal: The oncologist

Published: February 16, 2026

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Journal: Journal of Cancer

Published: December 16, 2025

Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R-Mutated Metastatic Pancreatic Adenocarcinoma.

Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R-Mutated Metastatic Pancreatic Adenocarcinoma.

Journal: JCO precision oncology

Published: December 10, 2025

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.

Journal: Cancer immunology, immunotherapy : CII

Published: December 02, 2025

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Journal: Cancer investigation

Published: October 10, 2025

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 17, 2025

Showing 1-12 of 56

Last Updated: 09/26/2026